This positions CD9 as a pivotal prognostic biomarker in glioma, offering independent prognostic value beyond established factors such as age, WHO grade, IDH mutation, and 1p19q codeletion status in multivariate Cox analysis. The gene discussed is CD9; the disease is central nervous system cancer.